You just read:

Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C including patients co-infected with HIV

News provided by

Boehringer Ingelheim (Canada) Ltd.

Nov 18, 2013, 07:00 ET